• Corpus ID: 12659396

A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma.

  title={A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma.},
  author={Yusuf Bayraktar and Ferhun Balkancı and Burhan Kayhan and Bedri Uzunalimoglu and Aytac Gokoz and Y. Yavuz Ozisik and Ahmet O Gurakar and David H. van Thiel and Di̇nçer Firat},
  volume={43 9},
BACKGROUND/AIMS The results of transcatheter arterial chemoembolization (TACE) in 28 cirrhotic patients with advanced hepatocellular carcinoma (HCC) were compared to those obtained in 15 cirrhotic patients with HCC treated with systemic chemotherapy, and 14 patients with HCC receiving no specific anti-cancer treatment. MATERIALS AND METHODS From November, 1986 through May 1994, 235 patients with HCC were seen by the investigators. Twenty eight of these patients actually received TACE. The… 

Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients.

Non-resorbable drug-eluting beads (DEBs) loaded with cytotoxic drugs have been developed and despite the theoretical advantages of this new device and the promising results of the pivotal studies, definitive data in favor of its superiority over cTACE are still lacking.

The Effects of Hepatic Artery Chemotherapy on Viral Hepatitis in Patients With Hepatocellular Carcinoma

It is concluded that neither TACE nor 90Y treatment was associated with worsening viral hepatitis in this group of HCC patients, and the presence of chronic viral hepatitis with normal bilirubin should not exclude the use of these therapies in patients with unresectable HCC.

Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma.

Patients who undergo hepatic arterial chemotherapy are not at an increased risk of developing hepaticarterial thrombosis or other hepatics arterial complications after orthotopic liver transplantation.

Arterial Embolization of Unresectable Hepatocellular Carcinoma with Use of Microspheres, Lipiodol, and Cyanoacrylate

A retrospective analysis of 46 patients with histologically confirmed hepatocellular carcinoma who were treated with transarterial embolization of the hepatic arteries found TAE with the use of microspheres and Lipiodol and cyanoacrylate for unresectable HCC is a feasible treatment modality.

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

In Asian patients with unresectable hepatocellular carcinoma, transarterial Lipiodol chemoembolization significantly improves survival and is an effective form of treatment.

Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art

Aim of this review is to summarize the main characteristics of drug-eluting beads (DEB)-TACE and the clinical results reported so far in the literature, and clear evidence of superiority of DEB-TACE over cTACE is still lacking.

Chemoembolization of hepatocellular carcinoma--what to tell the skeptics: review and meta-analysis.

A new, well-designed RCT would provide significant insight on the impact of chemoembolization on patient survival, as several non-randomized trials have clearly demonstrated a significant benefit of TACE on customer survival.

Transcatheter Arterial Chemoembolization of Liver Tumors: Effects of Embolization Protocol on Injectable Volume of Chemotherapy and Subsequent Arterial Patency

The slurry protocol (group 1) significantly reduced arterial patency and injectable volume of chemotherapy during TACE, which affects the totalVolume of chemotherapy injected into the liver as well as subsequent arterials patency.

Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow.

In this preliminary experience, intraarterial hepatic 131I iodized oil did not demonstrate high efficacy in the treatment of hepatocellular carcinoma in patients with portal venous thrombosis, as side effects were not rare.